Despite claiming success in a Phase III trial of human papillomavirus (HPV) candidate VGX-3100, shares in Inovio Pharmaceuticals (Nasdaq: INO) fell 15% on Tuesday, as investors worried over the strength of the data.
The Plymouth Meeting, USA-based company is developing the DNA-based vaccine for the treatment of three HPV-16-/18-related diseases – cervical dysplasia, vulvar dysplasia and anal dysplasia.
Inovio said the trial met primary and secondary endpoints “among all evaluable subjects."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze